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Kidney Res Clin Pract 31 (2012) A16–A96A94(Szczech et al. 2008 KI 74:791). In 2011, implementation of CMS ESRD
bundled payment and FDA-mandated ESA label changes that target lower
hemoglobin (Hb) created further downward pressure on ESA doses. Long-
term safety of intravenous (IV) iron is poorly understood. This study
evaluated temporal changes in the ratio of IV iron-to-epoetin use across
patients (N¼200,170) from a large dialysis organization from 2008
through 2011.
Mean IV iron use was normalized to mg/month. Mean epoetin was
normalized to U/month. The IV iron-to-epoetin ratio was calculated by
taking the mean IV iron value relative to mean epoetin (per 1000U/month)
for Q1 2008 – Q4 2011.
Although mean epoetin utilization has fallen since start of Q3 2010,
mean IV iron utilization has remained fairly stable. From Q1 2008 to Q3
2010, the ratio of IV iron-to-epoetin was constant (2.5 mg/month for every
1000 U per month), but has risen 46% from Q3 2010 to Q4 2011, while
hemoglobin levels have fallen 0.9 g/dL (11.5 to 10.6 g/dL).
While ESA doses decreased, iron doses remained constant, resulting in a
shift toward a higher ratio of iron-to-ESA use from Q3 2010 through Q4
2011. Further analyses are warranted to understand the appropriate
balance between iron and ESA use with regards to efﬁcacy and safety
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On average ESRD patients are hospitalized twice yearly for 12 days a year
(USRDS 2011 Ann. Report). Hb levels decline immediately post-
hospitalization, requiring extended periods for recovery and elevated ESA
dosing for 41 year (Solid et al. Hemodial Int. 2007). We evaluated post-
hospitalization anemia trends and ESA use in ESRD.
Data from an LDO (N¼273,877 pts; Q1 2008–Q1 2011) were evaluated
for post-hosp Hb change (difference, pre- and post-hosp Hb measurement),
time to Hb recovery (time from discharge to when Hb levels Z pre-hosp
level), time to ESA recovery (time from discharge until 3 consecutive non-
zero epoetin doses r pre-hosp dose) and incremental ESA (sum of all
differences from last pre-hosp dose until ESA recovery, 6 months if no
recovery, or end of follow-up for long-term follow-up population).
62% of all hospitalizations were associated with declining Hb (mean, -
1.29 g/dL; Figure); 54% of these never returned to pre-hosp levels. Among
hospitalizations that experienced a Hb drop and eventually recovered Hb
(mean recovery time, 42 days), 73% used a mean 56K U of incremental
epoetin until recovery; dose was recovered within 68 days on average. For
the remaining 27% who never returned to pre-hosp ESA dose, an additional
266K U of epoetin were utilized.
The majority of hospitalizations (2/3) had considerable post-hosp Hb
drops (mean 41 g/dL), with 450% permanently reduced. 1.5 months
were needed to recover Hb, with elevated ESA doses for 42 months. ESA
dose was permanently elevated in 27% of hospitalizations that recovered
Hb. Strategies to address post-hosp anemia may mitigate the protractedrecovery time and increased ESA use.
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Post hoc analysis of two Phase 3 pivotal trials (EMERALD 1,2) of
peginesatide vs epoetin for anemia due to chronic kidney disease in
hemodialysis patients on stable epoetin showed that for increasing doses of
baseline epoetin, relatively less peginesatide was needed to achieve similar
Hb levels (Fishbane et al, ASN 2011). Estimation of peginesatide should
therefore be dictated by underlying epoetin dose distribution rather than
total volume or mean epoetin dose in a population. This analysis compared
estimated peginesatide utilization for facilities using comparable levels of
epoetin.
Eight facilities from a large dialysis organization whose epoetin
utilization was within 71% of median utilization across all facilities from
Q4 2011 were compared. The label-speciﬁed dose conversion table was
used to convert weekly epoetin dose (deﬁned using all pt-months with Z1
dose) to monthly peginesatide dose for each facility
Comparison of total epoetin use (Q4 2011) from the 8 facilities showed
relative differences of o2% (range, 6.4-6.5M U). Facility utilization of post-
conversion peginesatide was estimated to range from 668-901 mg,
representing relative differences of up to 35% (Figure)
In contrast, calculations based on mean epoetin doses resulted in 41-
184% overestimation of peginesatide use.
Due to the nonlinear dose relationship between peginesatide and
epoetin, facilities with similar epoetin use (o2% relative difference) had up
to 35% difference in estimate of peginesatide use. For accurate estimation
of peginesatide utilization, it is important to base conversions on epoetin
dose distribution rather than mean epoetin dose.
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Many previous studies of renal transplant recipients have demonstrated
that weight gain post kidney transplantation (KT) is frequent and may
predispose to co morbidity. The aim of this prospective study was to
evaluate changes in body composition (BC) during the ﬁrst two years post
KT and to determine predictors of these changes, with a special focus on
pre KT parameters.
When listed for a KT, 41 patients (14 women - 27 men) were included
between 2007 and 2008 in a longitudinal study of evaluation of BC. Fat Free
